LOGIN  |  REGISTER
Terns Pharmaceuticals
Viking Therapeutics

Inari Medical to Present at the 43rd Annual Canaccord Growth Conference

July 26, 2023 | Last Trade: US$79.97 0.00 0.00

IRVINE, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the 43rd Annual Canaccord Growth Conference on Wednesday, August 9, 2023 at 4:00 p.m. Eastern Time at the InterContinental Boston Hotel in Boston, MA.

A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.

Investor Contact:
John Hsu, CFA
VP, Investor Relations
949-658-3889
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page